Price Will Begin to Increase in Sept., page-37

Well Affimed just went from $1s to over $7 with honestly JAZZ like potential on their deal with Roche ($96 million upfront, Affimed retains rights to up to $5B in milestones, Roche will pay development and commercialization of Affimed cancer drug platform. Affimed, much like Immuron, is a foregin stock that was completely ignored by the U.S. market. Hence why it was trading at $85M market cap before deal. A deal like that for Immuron would send Immuron through the sky and beyond with only 3.5 million shares. Affimed has 62 million shares.